Jade Biosciences (JBIO) Research & Development (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Research & Development came in at $36.1 million in Q1 2026, up 80.06% YoY from $20.0 million in Q1 2025, and up 2303.53% on a QoQ basis from $1.5 million in Q4 2025.
Jade Biosciences (JBIO) Research & Development (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Research & Development data on file, last reported at $36.1 million in Q1 2026.
- Quarterly Research & Development rose 80.06% year-over-year to $36.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $82.1 million (down 4.7% YoY) and the FY2025 annual result came in at $93.1 million, up 75.08% from the prior year.
- Research & Development grew to $36.1 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $36.1 million in Q1 2026 to a low of $1.5 million in Q4 2025.
- A 5-year average of $17.1 million and a median of $16.9 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 230.37% — and 2025, when it sank 95.2%.
- Tracing JBIO's Research & Development over 5 years: stood at $12.2 million in 2022, then surged by 45.76% to $17.8 million in 2023, then jumped by 75.34% to $31.2 million in 2024, then slumped by 95.2% to $1.5 million in 2025, then surged by 2303.53% to $36.1 million in 2026.
- The last three Research & Development figures came in at $36.1 million (Q1 2026), $1.5 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | 50.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.07 Mn |
| Mar 31, 2026 | 36.05 Mn |
| Dec 31, 2025 | 1.50 Mn |
| Sep 30, 2025 | 22.01 Mn |
| Jun 30, 2025 | 22.55 Mn |
| Mar 31, 2025 | 20.02 Mn |
| Dec 31, 2024 | 31.23 Mn |
| Sep 30, 2024 | 13.66 Mn |
| Jun 30, 2024 | 21.25 Mn |
| Mar 31, 2024 | 20.08 Mn |
| Dec 31, 2023 | 17.81 Mn |
| Sep 30, 2023 | 16.88 Mn |
| Jun 30, 2023 | 16.03 Mn |
| Mar 31, 2023 | 13.49 Mn |
| Dec 31, 2022 | 12.22 Mn |
| Sep 30, 2022 | 10.78 Mn |
| Jun 30, 2022 | 8.36 Mn |
| Mar 31, 2022 | 7.26 Mn |
| Dec 31, 2021 | 5.05 Mn |
| Sep 30, 2021 | 3.42 Mn |